ArticleBJU international2026
Validation of the Testicular Health Outcomes Report (THOR): a testicular cancer health-related quality of life instrument.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of modified surgical position on patients undergoing robot-assisted laparoscopic radical prostatectomy: a systematic review and meta-analysis.Journal of robotic surgery · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo evaluate the psychometric properties of the Testicular Health Outcomes Report (THOR) tool by assessing associations of disease burden and treatment received with health-related quality of life (HRQoL) domains. MATERIALS AND
methodsTHOR, which comprises 26 questions across 14 HRQoL domains, was administered electronically to patients presenting for known or suspected testicular cancer prior to clinical visits and throughout their care longitudinally. We evaluated construct validity by determining whether related constructs showed better correlation with disease and treatment burden than unrelated constructs. Generalised estimating equations were used for each domain or predictor of interest.
resultsBetween August 2022 and November 2024, 709 patients completed 906 surveys. More aggressive post-orchiectomy treatment - such as retroperitoneal lymph node dissection (RPLND), chemotherapy or post-chemotherapy RPLND - was associated with worse sexual function and problems with job/education. Patients undergoing nerve-sparing RPLND reported significantly better sexual function (22 points, 95% confidence interval 11, 33; P < 0.001) as compared to a non-nerve-sparing RPLND approach. Receipt of chemotherapy was associated with lower fertility confidence vs surveillance or primary RPLND (P = 0.005). Psychosocial domain scores and concern about disease relapse improved with time (P < 0.001). However, concern about relapse was not associated with initial clinical stage.
conclusionsThe THOR survey instrument is a valid measure of symptom burden and treatment received in men with testicular cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.